2,3-Dimethylphenylpiperazine

2,3-Dimethylphenylpiperazine (2,3-DMPP; code name PAL-218) is a monoamine releasing agent and designer drug of the phenylpiperazine family.^[1][2][3][4] It acts as a partial serotonin–norepinephrine releasing agent (SNRA), with EC₅₀Tooltip half-maximal effective concentration (E_maxTooltip maximal efficacy) values of 24 to 26 nM (85%) for serotonin, 13.7 to 56 nM (62%) for norepinephrine, and 1,207 to 1,320 nM (66%) for dopamine (22–96-fold lower than serotonin and norepinephrine).^[1][2] Its possible activities at serotonin receptors were not reported.^[1][2] The drug was first described in the scientific literature by 2009.^[3][1][2]

2,3-Dimethylphenylpiperazine

Clinical data
Other names	2,3-DMPP; 2,3-XP; PAL-218; PAL218
Drug class	Partial serotonin–norepinephrine releasing agent
Identifiers
IUPAC name 1-(2,3-dimethylphenyl)piperazine
CAS Number	1013-22-5
PubChem CID	70541
ChemSpider	63712
UNII	4J6RHZ6CSA
ChEMBL	ChEMBL2335161
CompTox Dashboard (EPA)	DTXSID60143826
ECHA InfoCard	100.012.540
Chemical and physical data
Formula	C12H18N2
Molar mass	190.290 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C(=CC=C1)N2CCNCC2)C
InChI InChI=1S/C12H18N2/c1-10-4-3-5-12(11(10)2)14-8-6-13-7-9-14/h3-5,13H,6-9H2,1-2H3 Key:LIKXJDINUMWKQA-UHFFFAOYSA-N

See also

• para-Nitrophenylpiperazine (pNPP; PAL-175)
• 3-Trifluoromethyl-4-chlorophenylpiperazine (TFMCPP; PAL-179)